Physician
Oncology
Dr. Amita Patnaik, MD
|
|
Give Review
Amita Patnaik practices Oncology. She received 1 awards: "Top Doctors:SE Texas". Amita Patnaik is a published physician. She has 70 papers published. The most current publication "Malignant colonic neoplasia in cats: 46 cases (1990-1996)." She is registered with Medicare and accepts Medicare payments.
Publications
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
- Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors.
- A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.
- A phase I first-in-human study of Nesvacumab (REGN910), a fully-human anti-Angiopoietin-2 (Ang2) monoclonal antibody, in patients with advanced solid tumors.
- A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.
- Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers.
- Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
- Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors.
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced Melanoma: a randomised dose-comparison cohort of a phase 1 trial.
- Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.
- Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in Cancer patients: Model prediction and clinical confirmation.
- A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors.
- A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.
- A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours.
- Phase I safety, pharmacokinetic and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.
- A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors.
- A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors.
- Evaluation of the Effects of Food on the Single-Dose Pharmacokinetics of Trametinib, a First-in-Class MEK Inhibitor, in Patients with Cancer.
- Safety and tumor responses with lambrolizumab (anti-PD-1) in Melanoma.
- A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.
- Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced Cancer.
- Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors.
- First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.
- Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.
- Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin.
- A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors.
- Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.
- Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid Malignancies.
- Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
- Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.
- Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
- Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients w...
- Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients...
- Panitumumab monotherapy in patients with previously treated metastatic colorectal Cancer.
- Erlotinib plus gemcitabine in patients with unresectable pancreatic Cancer and other solid tumors: phase IB trial.
- Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastat...
- Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptos...
- A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic Melanoma.
- Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
- Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
- Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with ...
- Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced Cancer patients with normal and impaired renal function.
- Raf: a strategic target for therapeutic development against Cancer.
- Biomarkers of anticancer activity of R115777 (Tipifarnib, Zarnestra) in human Breast cancer models in vitro.
- A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate Cancer.
- ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas.
- Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect...
- A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid Malignancies.
- A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
- A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in...
- A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced Malignancies.
- Regulation of c-Raf-1: therapeutic implications.
- A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.
- Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study.
- A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid Malignancies.
- Targeting intracellular signal transduction. A new paradigm for a brave new world of molecularly targeted therapeutics.
- A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid Malignancies.
- Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid Malignancies.
- Clinicopathologic and electron microscopic study of cutaneous neuroendocrine (Merkel cell) carcinoma in a cat with comparisons to human and canine tumors.
- Prognostic factors in dogs with urinary bladder carcinoma.
- Malignant colonic neoplasia in cats: 46 cases (1990-1996).
- Spinal tumors in 37 dogs: clinical outcome and long-term survival (1987-1994).
- Hemimaxillectomy for the treatment of oral tumors in 69 dogs.
- Results of partial mandibulectomy for the treatment of oral tumors in 142 dogs.
- Lymphomas in dogs. A morphologic, immunologic, and clinical study.
- Chemotherapy versus chemotherapy plus radiotherapy in the treatment of tonsillar squamous cell carcinoma in the dog.
- Canine osteoSarcoma. Treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin.
- Morphology of canine Ovarian Sertoli-Leydig cell neoplasms. A report of 12 cases.
- Efficacy and toxicity of doxorubicin and cyclophosphamide used in the treatment of selected malignant tumors in 23 cats.
Conditions Treated
- Anemia
- Breast Cancer
- Colorectal Cancer
- Esophageal Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Top Doctors:SE Texas
Education
-
University of Toronto Faculty of Medicine
Drug Facts
| NPI NUMBER | 1538162029 | |
| NPPES Provider LastName | PATNAIK | |
| NPPES Provider FirstName | AMITA | |
| NPPES Provider ZIPCode | 782293307 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 251.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 22.0 | |
| Percent Opioid Claims | 8.76 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1538162029 |
| Last Name Of The Provider | PATNAIK |
| First Name Of The Provider | AMITA |
| View All |
Similar Doctors
|
|
Dr. Sridhar Beeram, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lon S. Smith, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anand B. Karnad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ting-Wei Lu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tyler J. Curiel, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Allyson L. Harroff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Allison M. Garner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jesse E. Medellin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rudolfo P. Zarate Jr., MD
This Doctor is OpenDoctor Recommended.
|